ClinicalTrials.Veeva

Menu
U

Universitätsklinikum Freiburg | Klinik fur Dermatologie und Venerologie

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lenalidomide
Obinutuzumab
Dasatinib
Carboplatin
Dexamethasone
Atezolizumab
LX211
Docetaxel
Baricitinib
Octreotide

Parent organization

This site is a part of Universitätsklinikum Freiburg

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

42 of 179 total trials

"InDACtion" vs "3+7" Induction in AML

Older patients with acute myeloid leukemia (AML) have a small (\< 10%) chance of long-term survival. Despite the treatment of elderly AML patients wi...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: standard combination chemotherapy
Drug: decitabine

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), includ...

Enrolling
SM with an Associated Hematologic Neoplasm (SM-AHN)
Aggressive Systemic Mastocytosis (ASM)
Drug: bezuclastinib

The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung dise...

Enrolling
Chronic Lung Disease of Prematurity
Intraventricular Hemorrhage
Drug: OHB-607

This is an open label, single arm, interventional, prospective first in human study, designed to evaluate the safety of the NAO.VNS SYSTEM.

Enrolling
Drug Resistant Epilepsy
Device: VNS Treatment

This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Bas...

Active, not recruiting
Diffuse Cutaneous Systemic Sclerosis
Sclerosis, Systemic
Drug: Placebo
Drug: HZN-825 QD

The primary efficacy objective:To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24.The secondary effic...

Active, not recruiting
Idiopathic Inflammatory Myositis
Drug: Daxdilimab
Drug: Placebo

The Alternative-C Trial is a prospective, multicenter Phase 2 Study to evaluate the efficacy of the chemotherapy-free combination of copanlisib and o...

Active, not recruiting
Follicular Lymphoma
Drug: Obinutuzumab
Drug: Copanlisib

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medi...

Enrolling
Diabetes Mellitus, Type 2
Drug: Cagrilintide
Drug: Semaglutide

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Active, not recruiting
Type 2 Diabetes
Drug: Semaglutide
Drug: Cagrilintide

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to plac...

Enrolling
Sickle Cell Disease
Drug: Placebo Tablets
Drug: Etavopivat Tablets High dose
Locations recently updated

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell tr...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Iberdomide
Recently updated

Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram \[mg/kg\] and 200 mg/kg) of eteplirsen in appr...

Active, not recruiting
Muscular Dystrophy, Duchenne
Drug: Eteplirsen

This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in patients with International Society of N...

Active, not recruiting
Lupus Nephritis
Drug: Placebo
Drug: MMF

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of RO7303509 treatment in participants with systemic scl...

Active, not recruiting
Systemic Sclerosis
Drug: RO7303509
Drug: Placebo

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Active, not recruiting
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham

This study is open to adults with advanced cancer (solid tumors) and people with advanced head and neck cancer. The study has 2 parts. The purpose of...

Enrolling
Neoplasms
Drug: Ezabenlimab
Drug: BI 765179

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide
Locations recently updated

Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can partici...

Enrolling
Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Drug: BI 1839100
Drug: Placebo

The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whe...

Begins enrollment this month
Pyoderma Gangrenosum
Drug: Prednisolone
Drug: Prednisone

The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM202...

Active, not recruiting
Acromegaly
Drug: CAM2029 (octreotide subcutaneous depot)

Trial sponsors

Boehringer Ingelheim logo
U
Lilly logo
I
Amgen logo
Bayer logo
Genentech logo
L
J
U

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems